Please assess the completion status of the following clinical trial:

Trial Title: First-Line Treatment for HIV-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infection by HIV-2 only;~* Age \> ou = 18 years;~* Naïve for antiretroviral therapy (including antiretroviral treatment in the context of PMTCT except taking a dose of Nevirapine for PMTCT)~* CD4 \>200 cells/mm3~* Resident of the city where the study is held or of city suburbs to facilitate participation~* Signed informed consent document~Exclusion Criteria:~* Current participation in any other clinical trial~* Presence of opportunistic non-stabilized infections, of any serious or progressive disease, or of any clinical signs consistent with severe disease whose diagnosis is not yet confirmed, such as fever, weight loss, diarrhea or cough not yet explained (non-exhaustive list).~* All pathology that leads in daily life to prefer one or the other of the three therapeutic regimens for medical reasons or to change the dosages specified in the test. This includes (but not limited to):~* Hemoglobin ≤ 8 g / dL~* Neutrophil count \<500 cells/mm3~* Renal impairment with creatinine clearance \<50mL/mn~* Blood platelet \<50 000 cells/mm3~* Decompensated heart failure~* Hepatic failure Severe (TP\<50% or cytolysis severe (ALAT\> 3x ULN)~* Active TB during treatment with rifampicin~* Taking drugs that interact with the drugs of the clinical trial (as specified in the SPC)~* Pregnancy, breastfeeding or planning to become pregnant during study follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A : TDF + FTC (or 3TC) + ZDV (Type: EXPERIMENTAL): Tenofovir + Emtricitabine or Lamivudine + Zidovudine
- TDF+FTC (or 3TC) +LPV/r (Type: EXPERIMENTAL): Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
- Arm C : TDF +FTC (or 3TC) + RAL (Type: EXPERIMENTAL): Tenofovir + Emtricitabine or Lamivudine + Raltegravir

Based on this trial design, predict the completion outcome and termination type (if applicable).